Skin News and Research

RSS

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on November 10.

11 Nov 2015

LEO Pharma enters into Asset Purchase Agreement to acquire Astellas’ global dermatology business

LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, and Japanese pharmaceutical company Astellas Pharma Inc. today announced that they have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million.

11 Nov 2015

Study shows mindfulness meditation reduces pain more effectively than placebo

Scientists at Wake Forest Baptist Medical Center have found new evidence that mindfulness meditation reduces pain more effectively than placebo.

11 Nov 2015

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Data presented yesterday by researchers for Mallinckrodt plc, a leading specialty biopharmaceutical company, suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain measures of disease activity in patients with persistently active Systemic Lupus Erythematosus (SLE) who are receiving corticosteroid therapy.

10 Nov 2015

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

10 Nov 2015

Vitamin D deficiency puts people at risk of developing heart problems

A lack of vitamin D can result in weak bones. Recent studies also show that vitamin D deficiency is linked to more serious health risks such as coronary artery disease, heart attacks, and strokes.

10 Nov 2015

Inner ear damage brain warnings from nerve cells

Some nerve cells in the inner ear can signal tissue damage in a way similar to pain-sensing nerve cells in the body, according to new research from Johns Hopkins.

10 Nov 2015

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

Understanding how schizophrenia affects workings of the brain

Stem cells from adult schizophrenia patients form new proteins more slowly than those from healthy people, according to new research.

10 Nov 2015

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today.

9 Nov 2015

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

Paratek Pharmaceuticals, Inc. has announced the dosing of the first patient in its Phase 3 clinical study of its lead drug candidate, omadacycline, for the treatment of Community Acquired Bacterial Pneumonia (CABP). This global Phase 3 study will assess the efficacy and safety of omadacycline compared with moxifloxacin in subjects with CABP.

9 Nov 2015

First comprehensive genomic and biologic study of top skin disease-causing microbes

An international team of scientists, led by researchers from A*STAR's Genome Institute of Singapore (GIS), Institute of Medical Biology (IMB), and Bioinformatics Institute (BII), and P&G, have completed the first comprehensive genomic and biologic study of all species of Malassezia, one of the top skin disease-causing microbes.

9 Nov 2015

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

The presence of tophi - crystal deposits of uric acid found on the surface of the joints or in the skin and cartilage - in people with gout can increase their risk of developing cardiovascular disease, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco.

9 Nov 2015

No progression in joint damage in 84% of psoriatic arthritis patients

Novartis announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.

9 Nov 2015

Allergic response can be unexpected clue in medical mystery

Most people think of allergists as the doctors who help solve sneezing, wheezing and itchy eyes. They might not realize allergists are the medical mystery detectives with the expertise to discover what is causing all sorts of unusual allergic responses.

6 Nov 2015

Utah chemists devise new way to detect DNA damage

University of Utah chemists devised a new way to detect chemical damage to DNA that sometimes leads to genetic mutations responsible for many diseases, including various cancers and neurological disorders.

6 Nov 2015

Researchers identify seven genetic risk loci involved in atopic march

There's a typical "career" for some allergic people, and it starts very early on the skin: babies develop atopic dermatitis, food allergies may follow, then comes asthma and later on hay fever. A group of scientists led by Ingo Marenholz and Young-Ae Lee at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association, working with colleagues from several institutions, has now identified seven genetic risk loci for this course of disease.

6 Nov 2015

New tool could help identify patients most likely to benefit from chemoprevention

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

6 Nov 2015

Specific gut bacteria can improve cancer immunotherapy, show studies

By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers at the University of Chicago were able to boost the ability of the animal's immune systems to attack tumor cells. T

6 Nov 2015

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

RXi Pharmaceuticals Corporation a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology today announced the initiation of a Phase 1/2 clinical trial in ophthalmology. The clinical study RXI-109-1501 will evaluate the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases.

5 Nov 2015

Skin News and Research

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

LEO Pharma enters into Asset Purchase Agreement to acquire Astellas’ global dermatology business

Study shows mindfulness meditation reduces pain more effectively than placebo

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

Vitamin D deficiency puts people at risk of developing heart problems

Inner ear damage brain warnings from nerve cells

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Understanding how schizophrenia affects workings of the brain

New funding for Centenary's life saving research

Paratek initiates Omadacycline phase 3 clinical study in community acquired bacterial pneumonia (CABP)

First comprehensive genomic and biologic study of top skin disease-causing microbes

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

No progression in joint damage in 84% of psoriatic arthritis patients

Allergic response can be unexpected clue in medical mystery

Utah chemists devise new way to detect DNA damage

Researchers identify seven genetic risk loci involved in atopic march

New tool could help identify patients most likely to benefit from chemoprevention

Specific gut bacteria can improve cancer immunotherapy, show studies

RXi Pharmaceuticals begins Phase 1/2 clinical trial in ophthalmology

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News